Congenica will help clinicians and patients in China benefit from clinical genomics and personalised medicine
Congenica, the global diagnostic decision support platform provider, announced it has entered into an agreement with a new strategic partner, Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market.
The new partnership will see Congenica develop a version of its Sapientia™ platform designed to enable clinicians and patients in China to benefit from the clinical genomics and personalised medicine revolution. DCHealth will use its significant commercial depth and experience in the Chinese hospital market to accelerate the commercialization of this locally-adapted version of Sapientia™.
Campus research, innovation and engagement recognised at the 2022 Cambridge Independent Science and Technology Awards
The Cambridge Independent Science and Technology Awards took place on Wednesday evening at the Hinxton Hall Conference Centre. Campus teams, ...
13 May 2022Learn more
Birmingham 2022 Queen’s Baton Relay to visit Wellcome Genome Campus as full England route revealed
11 May 2022Learn more